Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-010281
Filing Date
2025-08-05
Accepted
2025-08-05 16:05:46
Documents
79
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rigl-20250630x10q.htm   iXBRL 10-Q 2494771
2 EX-10.1 rigl-20250630xex10d1.htm EX-10.1 176267
3 EX-10.2 rigl-20250630xex10d2.htm EX-10.2 145129
4 EX-31.1 rigl-20250630xex31d1.htm EX-31.1 15794
5 EX-31.2 rigl-20250630xex31d2.htm EX-31.2 16680
6 EX-32.1 rigl-20250630xex32d1.htm EX-32.1 8971
7 GRAPHIC rigl-20250630x10q005.jpg GRAPHIC 79278
  Complete submission text file 0001558370-25-010281.txt   10072981

Data Files

Seq Description Document Type Size
8 EX-101.SCH rigl-20250630.xsd EX-101.SCH 60152
9 EX-101.CAL rigl-20250630_cal.xml EX-101.CAL 61133
10 EX-101.DEF rigl-20250630_def.xml EX-101.DEF 224621
11 EX-101.LAB rigl-20250630_lab.xml EX-101.LAB 496671
12 EX-101.PRE rigl-20250630_pre.xml EX-101.PRE 365668
82 EXTRACTED XBRL INSTANCE DOCUMENT rigl-20250630x10q_htm.xml XML 1765627
Mailing Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-624-1100
RIGEL PHARMACEUTICALS INC (Filer) CIK: 0001034842 (see all company filings)

EIN.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-29889 | Film No.: 251184909
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)